Treatment with p38 inhibitor intensifies the death of MG132-treated As4.1 juxtaglomerular cells via the enhancement of GSH depletion
- PMID: 20545600
- DOI: 10.3109/01480540903483458
Treatment with p38 inhibitor intensifies the death of MG132-treated As4.1 juxtaglomerular cells via the enhancement of GSH depletion
Abstract
MG132, as a proteasome inhibitor, has been shown to induce apoptotic cell death through the formation of reactive oxygen species (ROS). In this study, we investigated the effects of MG132 and/or MAPK inhibitors on As4.1 juxtaglomerular cells in relation to cell growth, cell death, ROS, and glutathione (GSH) levels. MG132 inhibited the growth of As4.1 cells and induced cell death, accompanied by the loss of mitochondrial membrane potential (MMP; DeltaPsi(m)) and activation of caspase-3 and -8. MG132 increased ROS levels, and GSH depleted cell numbers. The MEK inhibitor slightly reduced cell growth and caspase-3 activity in MG132-treated As4.1 cells and mildly increased MMP (DeltaPsi(m)) loss and O(2)(*-) level. However, it did not increase apoptosis and GSH depletion. The JNK inhibitor did not strongly influence cell growth, cell death, and GSH depletion by MG132, but increased caspase-3 activity, MMP (DeltaPsi(m)) loss, and O(2)(*-) level. Treatment with the p38 inhibitor magnified cell-growth inhibition and apoptosis by MG132. This agent also strongly increased caspase-8 activity, MMP (DeltaPsi(m)) loss, O(2)(*-) level, and GSH depletion. Conclusively, the p38 inhibitor strongly intensified cell death in MG132-treated As4.1 cells. The changes of GSH content by MG132 and/or MAPK inhibitors were closely related to the death of As4.1 cells.
Similar articles
-
The changes of reactive oxygen species and glutathione by MG132, a proteasome inhibitor affect As4.1 juxtaglomerular cell growth and death.Chem Biol Interact. 2010 Mar 30;184(3):319-27. doi: 10.1016/j.cbi.2010.01.033. Epub 2010 Jan 25. Chem Biol Interact. 2010. PMID: 20100472
-
p38 inhibitor intensified cell death in antimycin A-treated As4.1 juxtaglomerular cells via the enhancement of GSH depletion.Anticancer Res. 2009 Nov;29(11):4423-31. Anticancer Res. 2009. PMID: 20032388
-
Proteasome inhibitor MG132 reduces growth of As4.1 juxtaglomerular cells via caspase-independent apoptosis.Arch Toxicol. 2010 Sep;84(9):689-98. doi: 10.1007/s00204-010-0550-8. Epub 2010 May 7. Arch Toxicol. 2010. PMID: 20449726
-
The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner.Oncol Res. 2010;18(7):315-22. doi: 10.3727/096504010x12626118079949. Oncol Res. 2010. PMID: 20377132
-
Imbalanced GSH/ROS and sequential cell death.J Biochem Mol Toxicol. 2022 Jan;36(1):e22942. doi: 10.1002/jbt.22942. Epub 2021 Nov 2. J Biochem Mol Toxicol. 2022. PMID: 34725879 Review.
Cited by
-
Preventive and therapeutic effects of MG132 by activating Nrf2-ARE signaling pathway on oxidative stress-induced cardiovascular and renal injury.Oxid Med Cell Longev. 2013;2013:306073. doi: 10.1155/2013/306073. Epub 2013 Mar 7. Oxid Med Cell Longev. 2013. PMID: 23533688 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials